Literature DB >> 14673956

Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL-1beta with IL-1beta acting as a modulator of cellular differentiation.

Martin Albrecht1, Jolanta Doroszewicz, Sonja Gillen, Iara Gomes, Beate Wilhelm, Thomas Stief, Gerhard Aumüller.   

Abstract

BACKGROUND: Neutral endopeptidase (NEP) is a cell-surface bound enzyme that cleaves and inactivates neuropeptides such as bombesin and substance P and is involved in the transition from hormonally regulated androgen-dependent prostate cancer (PC) to androgen-independent PC. Neuropeptides are implicated in growth regulation of different cell types and function as transmitters between the neuroendocrine and the immune system.
METHODS: NEP-expression, enzymatic activity of the membrane bound protein, cell proliferation, procalcitonin (PCT) production, and secretion as well as changes in cell morphology of prostatic cells were evaluated after treatment with the immunomodulatory cytokine interleukin-1beta (IL-1beta), neuropeptides (bombesin, substance P), and neuropeptide-conditioned media derived from a human neuroendocrine cell line.
RESULTS: Incubation of LNCaP tumor cells with IL-1beta resulted in a diminished proliferative activity, induction of neurite-like outgrowth which was accompanied by the formation of tubular-type mitochondria typical for neuronal/neuroendocrine cells, and an increased production and secretion of PCT. Conversely, proliferation of prostatic stromal cells was enhanced by the cytokine coming along with an increased number of Golgi-apparatuses and ER-cisternae. Bombesin had an antimitotic effect on LNCaP, but not on stromal cells. Substance P did not influence the growth of any of the cell types investigated, whereas neuropeptide-conditioned media exerted a slightly mitogenic effect on both cell types. The activity of LNCaP cell-surface bound NEP was enhanced by bombesin, but was diminished by substance P and neuropeptide-conditioned media.
CONCLUSIONS: Proliferation and activity of neuropeptide degrading NEP is regulated differently by immunomodulatory substances in PC cells and cells derived from the prostatic stroma with IL-1beta being a potent modulator of cellular differentiation and a potential target for anticancer drug design in PC cells. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14673956     DOI: 10.1002/pros.10288

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  12 in total

1.  Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.

Authors:  Sven Gunia; Knut Albrecht; Stefan Koch; Thomas Herrmann; Thorsten Ecke; Volker Loy; Jörg Linke; Michael Siegsmund; Matthias May
Journal:  World J Urol       Date:  2008-04-05       Impact factor: 4.226

2.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

3.  Gene network and canonical pathway analysis in prostate cancer: a microarray study.

Authors:  Hakan Savli; Attila Szendröi; Imre Romics; Balint Nagy
Journal:  Exp Mol Med       Date:  2008-04-30       Impact factor: 8.718

4.  IL-1β induces p62/SQSTM1 and represses androgen receptor expression in prostate cancer cells.

Authors:  M A Chang; V Patel; M Gwede; M Morgado; K Tomasevich; E L Fong; M C Farach-Carson; Nikki A Delk
Journal:  J Cell Biochem       Date:  2014-12       Impact factor: 4.429

5.  Comparative study of 64Cu/NOTA-[D-Tyr6,βAla11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging.

Authors:  Patrick Fournier; Véronique Dumulon-Perreault; Samia Ait-Mohand; Réjean Langlois; François Bénard; Roger Lecomte; Brigitte Guérin
Journal:  EJNMMI Res       Date:  2012-02-14       Impact factor: 3.138

6.  Cytokine effects on cell viability and death of prostate carcinoma cells.

Authors:  Georgios Chondrogiannis; Michalis Kastamoulas; Panagiotis Kanavaros; Georgios Vartholomatos; Maria Bai; Dimitrios Baltogiannis; Nikolaos Sofikitis; Dimitrios Arvanitis; Vasiliki Galani
Journal:  Biomed Res Int       Date:  2014-05-29       Impact factor: 3.411

Review 7.  Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine?

Authors:  Alexandru Dan Grigore; Eshel Ben-Jacob; Mary C Farach-Carson
Journal:  Front Oncol       Date:  2015-03-03       Impact factor: 6.244

8.  In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.

Authors:  Kristell L S Chatalic; Mark Konijnenberg; Julie Nonnekens; Erik de Blois; Sander Hoeben; Corrina de Ridder; Luc Brunel; Jean-Alain Fehrentz; Jean Martinez; Dik C van Gent; Berthold A Nock; Theodosia Maina; Wytske M van Weerden; Marion de Jong
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

9.  Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.

Authors:  Yu-Hua Huang; Ya-Qun Zhang; Jiao-Ti Huang
Journal:  Asian J Androl       Date:  2019 May-Jun       Impact factor: 3.285

10.  IL-1-conferred gene expression pattern in ERα+ BCa and AR+ PCa cells is intrinsic to ERα- BCa and AR- PCa cells and promotes cell survival.

Authors:  Afshan F Nawas; Mohammed Kanchwala; Shayna E Thomas-Jardin; Haley Dahl; Kelly Daescu; Monica Bautista; Vanessa Anunobi; Ally Wong; Rachel Meade; Ragini Mistry; Nisha Ghatwai; Felix Bayerl; Chao Xing; Nikki A Delk
Journal:  BMC Cancer       Date:  2020-01-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.